title: Human leukocyte antigens as genetic markers in Greek patients with sporadic pancreatic cancer.
abstract: OBJECTIVE
  In this study we investigated the relationship between specific HLA antigens and sporadic pancreatic cancer in Greek population.
  
  
  METHODS
  The allele frequencies of serologically and molecular defined class I and II HLA antigens were studied in 60 unrelated patients with pancreatic cancer histologically confirmed. The results obtained for HLA frequencies were compared with those of 105 healthy control subjects (control group).
  
  
  RESULTS
  Increased frequencies of HLA-A30 (16.7 vs. 3.8%; P < 0.01; OR = 5.05), A31 (9.5 vs. 1.9%; P < 0.05; OR = 5.72), B18 (31.7 vs. 14.3%; P < 0.05; OR = 2.78) and Cw7 (53.3 vs. 21.9%; P < 0.01; OR = 4.07) were observed in patients with pancreatic cancer in comparison to the control subjects.
  
  
  CONCLUSIONS
  This study demonstrates the association between specific HLA antigens and pancreatic cancer development in whites and suggests a genetic susceptibility factor for the disease.
authors.affiliation: First Propaudeutic Surgical Department, School of Medicine, University of Athens, Greece. ikouerinis@hotmail.com
authors.forename: I A
authors.initials: IA
authors.lastname: Kouerinis
authors.forename: G
authors.initials: G
authors.lastname: Zografos
authors.forename: K E
authors.initials: KE
authors.lastname: Tarassi
authors.forename: T H
authors.initials: TH
authors.lastname: Athanasiades
authors.forename: M
authors.initials: M
authors.lastname: Liontos
authors.forename: V G
authors.initials: VG
authors.lastname: Gorgoulis
authors.forename: D
authors.initials: D
authors.lastname: Korkolis
authors.forename: M M
authors.initials: MM
authors.lastname: Konstandoulakis
authors.forename: C I
authors.initials: CI
authors.lastname: Fotiadis
authors.forename: G
authors.initials: G
authors.lastname: Androulakis
authors.forename: C A
authors.initials: CA
authors.lastname: Papasteriades
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000437:Alcoholism / Q000453:epidemiology; D000951:Antigens, Neoplasm / Q000032:analysis* / Q000235:genetics; D015897:Comorbidity; D003924:Diabetes Mellitus, Type 2 / Q000453:epidemiology; D005260:Female; D005787:Gene Frequency; D005805:Genes, MHC Class I; D005802:Genes, MHC Class II; D005819:Genetic Markers; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006115:Greece / Q000453:epidemiology; D006680:HLA Antigens / Q000032:analysis* / Q000235:genetics; D015234:HLA-A Antigens / Q000032:analysis / Q000235:genetics; D015235:HLA-B Antigens / Q000032:analysis / Q000235:genetics; D059911:HLA-B18 Antigen; D015236:HLA-C Antigens / Q000032:analysis / Q000235:genetics; D006650:Histocompatibility Testing; D006801:Humans; D008297:Male; D008875:Middle Aged; D010190:Pancreatic Neoplasms / Q000453:epidemiology / Q000235:genetics* / Q000276:immunology; D044465:White People / Q000235:genetics
chemical_list: D000951:Antigens, Neoplasm; D005819:Genetic Markers; D006680:HLA Antigens; D015234:HLA-A Antigens; C069526:HLA-A*30 antigen; C069527:HLA-A31 antigen; D015235:HLA-B Antigens; D059911:HLA-B18 Antigen; D015236:HLA-C Antigens; C040178:HLA-C*70 antigen